Relying on its strong R&D team, HGT provides various multi-pathogen detection kits for clinical use, offering basis for clinical diagnosis and medication to infectious diseases patients.

The Multiplex Testing Kit for 13 Respiratory Pathogens covers viruses of clinically high positive rates and high-risk severe cases, achieves multi-pathogens joined detection, and provides comprehensive, accurate and fast testing results for the clinical diagnosis of acute respiratory infections and distinguish it from that of COVID-19.

Targeting carcinogenic genes E6/E7, HGT's 25 Multiplex HPV DNA Genotyping Kit covers NMPA-specified 18 high-risk HPV types. The kit has an anti-contamination system and includes double internal control to safe-guard the quality of the testing to minimize false negative result. It supports cervical cancer screening, promotes women health services, and contributes to the global effort in fighting cervical cancer.

HGT provides a “safe, stable and convenient” sample processing system to ensure zero infection to every operator.

Based on the advanced fragment analysis technology, HGT’s instrument platform makes the setup of multi-pathogen nucleic acid testing system faster, simpler and more efficient.

To assist doctors in determining drug and dosage accurately for each patient according to their unique, individual genotype, advanced fragment analysis technology is applied to identify drug-related genes in different individuals (drug metabolism enzyme, transporter and receptor genes).